A Review of Neurogenic Stunned Myocardium. by Biso, Sylvia et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Medicine Faculty Papers Department of Medicine
8-10-2017
A Review of Neurogenic Stunned Myocardium.
Sylvia Biso
Einstein Medical Center
Supakanya Wongrakpanich
Einstein Medical Center
Akanksha Agrawal
Einstein Medical Center
Sujani Yadlapati
Einstein Medical Center
Marina Kishlyansky
Einstein Medical Center
See next page for additional authors
Let us know how access to this document benefits you
Follow this and additional works at: https://jdc.jefferson.edu/medfp
Part of the Cardiology Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Medicine Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Biso, Sylvia; Wongrakpanich, Supakanya; Agrawal, Akanksha; Yadlapati, Sujani; Kishlyansky,
Marina; and Figueredo, Vincent M., "A Review of Neurogenic Stunned Myocardium." (2017).
Department of Medicine Faculty Papers. Paper 212.
https://jdc.jefferson.edu/medfp/212
Authors
Sylvia Biso, Supakanya Wongrakpanich, Akanksha Agrawal, Sujani Yadlapati, Marina Kishlyansky, and Vincent
M. Figueredo
This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/medfp/212
Review Article
A Review of Neurogenic Stunned Myocardium
Sylvia Biso,1 SupakanyaWongrakpanich,1 Akanksha Agrawal,1 Sujani Yadlapati,1
Marina Kishlyansky,1 and Vincent Figueredo2,3
1Department of Internal Medicine, Einstein Medical Center, Philadelphia, PA, USA
2Einstein Institute for Heart and Vascular Health, Einstein Medical Center, Philadelphia, PA, USA
3Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA
Correspondence should be addressed to Sylvia Biso; bisosylv@einstein.edu
Received 29 April 2017; Accepted 2 July 2017; Published 10 August 2017
Academic Editor: Eugene Nalivaiko
Copyright © 2017 Sylvia Biso et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Neurologic stunned myocardium (NSM) is a phenomenon where neurologic events give rise to cardiac abnormalities. Neurologic
events like stroke and seizures cause sympathetic storm and autonomic dysregulation that result in myocardial injury. The clinical
presentation can involve troponin elevation, left ventricular dysfunction, and ECG changes.These findings are similar to Takotsubo
cardiomyopathy and acute coronary syndrome. It is difficult to distinguish NSM from acute coronary syndrome based on clinical
presentation alone. Because of this difficulty, a patient with NSMwho is at high risk for coronary heart disease may undergo cardiac
catheterization to rule out coronary artery disease. The objective of this review of literature is to enhance physician’s awareness of
NSM and its features to help tailor management according to the patient’s clinical profile.
1. Introduction
Every year, an estimated 800,000 people in the United States
have a new or recurrent stroke. Roughly every 40 seconds, a
person experiences a stroke, and every 4 minutes, a person
dies from one [1]. Stroke is a significant cause of major long-
term functional disability [2]. Cardiovascular complications
are common after an acute stroke [3]. Neurologic events
have been known to cause cardiac abnormalities ranging
from arrhythmias, ventricular dysfunction, and myocardial
infarction to sudden cardiac death [4]. In a study by Chin
et al., approximately 13% of patients had an associated acute
myocardial infarction within 3 days of a cerebrovascular
accident [5]. During the first month after a stroke, cardiac
events account for the most common nonneurologic cause of
mortality [6]. In addition, the most common cause of death
on long-term follow-up after a cerebrovascular accident is
annual cardiac mortality [7]. Even 3 to 4 years after a stroke,
there is still a 2% annual risk of myocardial infarction [8].
Neurogenic myocardial injury, such as neurogenic
stunned myocardium (NSM), is a phenomenon where car-
diac complications occur after a neurologic event (i.e., stroke,
subarachnoid hemorrhage, or seizures) due to dysregulation
of the autonomic nervous system [9]. It can manifest as
almost any cardiac disturbance [10]. NSM oftentimes can
be very similar to myocardial infarction, presenting with
ischemic ECG changes, decreased cardiac function, elevated
troponin levels, and ventricular wall abnormalities [11, 12]. A
surge of catecholamines after areas of the brain governing the
autonomic system have been damaged has been suggested as
a potential mechanism [13]. Unlike myocardial infarction,
where coronary arteries are blocked, there is no significant
obstruction of the coronary vessels in patients with an NSM
causing the myocardial infarction-like signs and symptoms.
A study by Kono et al. on subarachnoid hemorrhage patients
who had ST-segment elevation and corresponding wall
motion abnormalities on echocardiogram revealed no coro-
nary artery stenoses or vasospasm of epicardial arteries on
coronary angiography [14].
NSM after acute ischemic stroke or subarachnoid hem-
orrhage is similar to Takotsubo cardiomyopathy in presen-
tation. They both mimic myocardial infarction and have
transient left ventricular hypokinesis [15]. Takotsubo car-
diomyopathy usually presents with a regional wall motion
abnormality, while NSM shows global hypokinesis. Due to
their catecholamine-mediated natures, both are thought to
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have the same pathophysiology and follow the same course of
illness [16]. In terms of treatment, both are reversible and are
medically managed [17]. Some believe that they are the same
entity and that they should both fall under stress-induced
cardiomyopathy [18, 19].
Distinguishing myocardial injury caused solely by a neu-
rologic event from an acute myocardial infarction is difficult.
For patients with subarachnoid hemorrhage, Bulsara et al.
[20] recommended the following guidelines for distinguish-
ing NSM from acute myocardial infarction: (1) no history of
heart disease, (2) new onset of cardiac dysfunction (ejection
fraction < 40%), (3) wall motion abnormalities that do not
correspond to ischemic ECG changes, and (4) troponin
values less than 2.8 ng/ml in patients with EF < 40%. Unlike
subarachnoid hemorrhage patients, however, acute ischemic
stroke patients commonly have preexisting heart disease and
extensive atherosclerotic disease [21]. These criteria do not
apply to them.The objective of this review of literature, thus,
is to enhance physician’s awareness of NSM and its features
to help in the differential diagnosis and assist in tailoring the
management according to the patient’s clinical profile.
2. Neuroanatomic Correlates
Studies have demonstrated that involvement of the insular
cortex during stroke results in autonomic dysregulation and
adverse cardiac outcomes [22].The insular cortex, considered
the “hidden fifth lobe,” is situated at the base of the Sylvian
fissure. Grossly, it consists of the anterior and posterior
insula, bisected by the central insular sulcus [23]. The insula
integrates autonomic, motor, and sensory functions through
its reciprocal connections with other parts of the brain,
notably the limbic system [24]. It is particularly important
for gustatory sensation, articulation planning and execution,
vestibular function, and control of the autonomic nervous
system [25]. Its importance in the pathophysiology of NSM
lies in its ability to maintain the balance between the sympa-
thetic and parasympathetic system.
The insula has a major role in cardiovascular regulation,
specifically in limbic-autonomic regulation [26]. The insular
cortex contains baroreceptive units of sympathoexcitatory
and sympathoinhibitory neurons that regulate blood pressure
and heart rate. Stimulation or injury of the insula gives rise to
changes in these cardiovascular parameters. Lesions in this
part of the brain have been found to result in an increase in
norepinephrine levels in the blood which cause left ventric-
ular dysfunction [27]. Stimulation of the right insula elicited
sympathetic effects like tachycardia and hypertension, while
stimulation of the left insula resulted in parasympathetic
responses such as bradycardia and vasodepressor effects [28].
A left insular stroke has been shown to cause depressed
parasympathetic regulation and increased sympathetic tone.
The reverse is true for right insular stroke [7]. Both right and
left insular lesionsmay also result in decreased heart rate vari-
ability. Although data vary regarding which side ismore asso-
ciated with adverse cardiac outcomes, both have been associ-
ated with increased cardiac morbidity and mortality [29].
The parietal lobe has also been associated with NSM
but its role is less clear. The parietal lobe and the insula
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Figure 1: Pathophysiology of NSM.
are supplied by the same blood vessel, the middle cerebral
artery. Because of this, when the insula suffers an ischemic
insult, the parietal lobe is also affected. It has been postulated
that the insula is the one causing the myocardial injury
and the parietal lobe happens to be a “bystander” [25].
A large study by Rincon et al., however, did not support
these findings [30]. Its results showed that the parietal lobe
stroke was an independent predictor for cardiac death or
myocardial infarction. By contrast, insular cortex lesions had
no correlation to cardiac events. However, in this study, only
40% of the patients had an MRI. The study relied heavily on
CT scans that could have led to misclassification of the stroke
lesions. Another limitation of the studywas that the studywas
not primarily designed to find the neuroanatomic correlates
of NSM. The results obtained were only a secondary analysis
of their data. Thus, more research is needed to clarify the
extent of the influence of the parietal lobe on NSM.
3. Pathophysiology
Excessive sympathetic stimulation is the underlying mecha-
nism for neurogenic myocardial injury (Figure 1). The cas-
cade of events starts with an influx of catecholamines from
a neurologic lesion or extreme stress. Cardiac injury then
happens in three possible ways: (1) coronary vasospasm
secondary to the catecholamine surge [11], (2) ischemia via
increase in myocardial demand [9], and (3) direct toxic
effects of catecholamines on the myocardium [31]. Toxic
effects of catecholamines can occur via calcium overload
of the cardiomyocytes [32]. Excessive stimulation of the
B-adrenergic receptors by catecholamines opens calcium
channels. The abnormal amount of calcium into the cells
causes contractile dysfunction and adenosine triphosphate
(ATP) depletion. ATP depletion then leads to mitochondrial
dysfunction culminating in cell death [9].
The resulting histopathology of NSM is different from
those found in patients with myocardial infarction. In
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Figure 2: New T-wave inversions in inferolateral leads in a patient
with NSM.
patients with coronary artery disease, histopathology shows
myocardial necrosis in the distribution of the coronary
arteries [13]. Neurogenic cardiac injury, in contrast, is pre-
dominantly myofibrillar degeneration or myocytolysis that
is transient and distinct from myocardial necrosis. Myocy-
tolysis or myofibrillar degeneration denotes acute myocar-
dial stress and is characterized by foci of subendocardial
hemorrhage surrounding epicardiac nerves [33]. Because of
the myocytolysis’ subendocardial location where the cardiac
conducting system is also present, arrhythmias are common
in NSM [24].
4. Electrocardiographic Features
Abnormal ECG findings can be observed in 60%–90% of
cerebral infarction patients (Figure 2) [34]. The most com-
mon morphologic change is a prolonged QT interval. This
is followed by T-wave inversions and then ST-depression
[35]. The most common rhythm change is atrial fibrillation
followed by sinus tachycardia [36]. A triad of ECG findings,
QT prolongation and U waves and T waves’ inversion, which
are associated with acute neurologic lesions, were seen in 8%
of patients after a cerebral infarction [35].
A study byDogan and colleagues observed ischemic ECG
changes in 90% of ischemic and hemorrhagic stroke patients
regardless of whether they have history of cardiac disease or
not [37]. The most common ECG changes were nonspecific
ST-T wave changes, followed by ST-segment depression [38,
39]. A study by McDermott et al. found that ST-segment
change is an independent predictor of early death and is the
most important long-term prognostic factor apart from age
[40, 41]. In Dogan et al.’s study, ischemic ECG changes were
not associated with mortality, but history of cardiac disease
was found to be an independent predictor of mortality [37].
Others have attempted to map ECG abnormalities to specific
brain locations; however, no strong associations have been
found [42].
Arrhythmias are common after stroke and they occur
more frequently in patients with cardiac disease. Other
predictors for cardiac arrhythmias after stroke are older
age, hypertension, and diabetes mellitus [43]. The National
Institutes ofHealth Stroke Scale (NIHSS) score is an indepen-
dent predictor for the appearance of arrhythmias. Thus, the
NIHSS score on admission could be used to stratify patients
and find out who needs cardiac monitoring after 24 hours.
Arrhythmias found in acute stroke in the order of frequency
are atrial fibrillation, sinus tachycardia, premature ventricular
complexes, and ventricular tachycardia [44, 45].
5. 2D Echocardiographic Features
NSM can present with left ventricular dysfunction [18]. A
study by Banki et al. in subarachnoid hemorrhage patients
with cardiac dysfunction observed that the patients’ wall
motion abnormalities on echocardiograms matched their
ECG changes [19]. However, in another study by Bulsara,
involving acute ischemic cerebral infarct patients, echocar-
diograms did notmatch their ECG findings. Average ejection
fraction was found to be 33%. After 5 days, cardiac output
improved by 1.6 L/minute [20]. In patients with subarach-
noid hemorrhage, reversal of wall motion abnormalities was
observed in 2 days [9].
6. Troponin Levels
NSM can be asymptomatic and underdiagnosed in stroke
patients. Elevated troponin levels in patients with ischemic
stroke can occur without corresponding chest pain, ECG
changes, or echocardiographic changes. It can be the only
sign of cardiac injury. In a study by Faiz and colleagues,
elevated troponin T levels occurred in 53% of acute ischemic
stroke patients. Only 6% of patients, however, met the criteria
for MI [46]. In another study by Jensen et al. of patients
without overt ischemic heart disease, elevated troponin levels
occurred only in 3% [47]. Presence of congestive heart failure
or renal failure can account for the increase in troponin levels
in these patients.
There are many factors that are independently related
to increased troponins in stroke patients. These include age,
previous coronary artery disease, congestive heart failure,
diabetes, hypercholesterolemia, and chronic kidney disease.
Stroke patients with involvement of the insula are more
commonly found to have increased troponin levels. When
patients with chronic kidney disease and coronary artery
disease were excluded, only insular involvement was found
to be significantly related to elevated troponin levels [48, 49].
Elevated troponinT levels were also found to predict poor
outcome in patients with acute stroke. In a study by Ghali et
al., troponin was found to have sensitivity of 0.27, specificity
of 0.94, and likelihood ratio (LR) of 4.5 for predicting a poor
outcome after ischemic stroke [50, 51]. Troponin was also
correlated to the severity of stroke [50]. However, NIHSS has
been proven to be a stronger predictor of adverse outcomes.
It has stronger sensitivity (0.78), specificity (0.96), and LR
(17.7) compared to troponin T [51]. Another study by Jensen
et al. found that patients with increased troponin levels
were at increased risk of death in the hospital and within
the following 2 years [47, 50]. Studies regarding troponin
levels and acute ischemic stroke are abundant but limited
by the heterogeneity of laboratory assay, different laboratory
references, and cut-offs for what constitutes a significant
elevation [52, 53].
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7. Management
Silent coronary artery disease has been found to be prevalent
in patients with acute ischemic stroke [54]. Coronary heart
disease and ischemic stroke have the same risk factors and
they tend to occur in the same subset of patients [55].
Given the concurrence of acute ischemic stroke and cardiac
abnormalities, evaluation for myocardial dysfunction and
injury is important in these patients. This is especially true as
cardiac abnormalities that can occur are often asymptomatic,
possibly because of the decreased cognitive and functional
capacities of stroke patients. Furthermore, cardiac events
are also a major cause of mortality and morbidity in these
patients [6].
An American Heart Association/American Stroke Asso-
ciation (AHA/ASA) statement recommends that patients
with ischemic stroke or TIA undergo cardiovascular risk
assessment and aggressive risk reduction management [56].
They further recommend that patients with multiple coro-
nary artery disease risk factors or high Framingham risk
score (i.e., 10-year coronary heart disease risk >/= 20%)
should be considered for noninvasive coronary artery disease
testing. ACC/AHA practice guidelines, in addition, can help
determine which diagnostic test for coronary heart disease
can be used [57]. Finally, the decision to institute medical,
endovascular, or surgical management must be tailored
according to patient’s clinical profile.
On the other hand, if the cardiac abnormality is likely
from NSM, such as in subarachnoid hemorrhage patients,
coronary angiography is not routinely recommended. In
a study by Kono and colleagues involving subarachnoid
patients with ST-segment elevation [14], coronary angiogra-
phy revealed no stenosis or vasospasm of coronary arteries.
However, a strong clinical suspicion of plaque rupture or
high burden of atherosclerosis may still warrant coronary
angiography.
8. Conclusion
Cardiovascular complications in the setting of neurologic
events are diverse in presentation and can produce adverse
outcomes. The pathophysiology involves excessive cate-
cholamine release during a neurologic injury that produces
increased cardiac demand, stress, and myocytolysis. Most
studies showed that the insular cortex is mostly involved in
causing this autonomic dysregulation, especially in stroke
patients. The resulting clinical manifestations are varied
and can mimic acute coronary syndromes. It is difficult, if
not impossible, to distinguish NSM from acute coronary
syndrome based on clinical manifestations alone. There are
also no clear guidelines on how to manage NSM. In patients
with risk factors for coronary heart disease, cardiovascular
risk assessment, aggressive cardiovascular risk reduction, and
tailoring the management intomedical, endovascular, or sur-
gical management depending on the clinical characteristics
of the patient are currently employed.
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